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Background: Thymidine kinase 1 (TK1) is a salvage enzyme involved in DNA precursor synthesis, and its expression
is proliferation dependent. A serum form of TK1 has been used as a biomarker in human medicine for many years
and more recently to monitor canine lymphoma. Canine TK1 has not been cloned and studied. Therefore, dog and
human TK1 cDNA were cloned and expressed, and the recombinant enzymes characterized. The serum and cellular
forms of canine and human TK1 were studied by size-exclusion chromatography and the level of TK1 protein was
determined using polyclonal and monoclonal anti-TK1 antibodies.
Results: Canine TK1 phosphorylated the thymidine (dThd) analog 3'-azido-thymidine (AZT) as efficiently as it did
dThd, whereas AZT phosphorylation by human TK1 was less efficient than that of dThd. Dog TK1 was also more
thermostable and pH tolerant than the human enzyme. Oligomeric forms were observed with both enzymes in
addition to the tetrameric and dimeric forms. Cellular TK1 was predominantly seen in dimeric and tetrameric forms,
in the case of both dog TK1 from MDCK cells and human TK1 from CEM cells. Active serum TK1 was found mainly
in a high molecular weight form, and treatment with a reducing agent shifted the high molecular weight complex
to lower molecular weight forms with reduced total activity. Western blot analysis demonstrated a polypeptide of
26 kDa (dog) and 25 kDa (human) for cellular and serum TK1. There was no direct correlation between serum TK1
activity and protein level. It appears that a substantial fraction of serum TK1 is not enzymatically active.
Conclusions: These results suggest that the serum TK1 protein differs from cellular or recombinant forms, is more
active in high molecular weight complexes, and is sensitive to reducing agents. The results presented here provide
important information for the future development and use of serum TK1 as a diagnostic biomarker in human and
veterinary medicine.
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Thymidine kinase (ATP: thymidine 5'- phosphotransfer-
ase, EC 2.7.1.21) is an enzyme involved in DNA precur-
sor synthesis. It phosphorylates thymidine to dTMP,
which is then further phosphorylated to thymidine di-
phosphate (dTDP) and triphosphate (dTTP) [1].
Thymidine kinase 1 (TK1) shows an S-phase dependent
expression; TK1 activity increases in late G1 phase,
reaches peak values during the S phase, and then decreases
in the M phase. Accordingly, high levels of TK1 are found* Correspondence: liya.wang@slu.se
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reproduction in any medium, provided the orin proliferating and malignant cells and tissues [2-4].
Human TK1 has been extensively studied [5-7] and native
human TK1 is found in two forms, a dimer form with low
thymidine affinity (Km=15 μM) and a tetramer form with
high thymidine affinity (Km=0.7 μM). ATP is a positive
regulator in the tetramerization of human TK1 [6]. Recent
structural studies of a TK1-like enzyme suggest that the
binding of ATP leads to reorganization of the enzyme qua-
ternary structure [8,9].
A form of TK1 is found at high levels in the sera of
humans and animals with malignant tumors; therefore,
serum TK1 activity has been used as a prognostic marker
for several different tumor types, but primarily in
leukemia and lymphoma [10-12].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hanan et al. BMC Biochemistry 2012, 13:12 Page 2 of 10
http://www.biomedcentral.com/1471-2091/13/12Serum TK1 activity can be measured using a radio-
active substrate analogue (Prolifigen TK-REA) [13] and
this radio-enzymatic assay has been used in dogs with
malignant lymphoma to predict the relapse of disease
and to follow up therapy [14]. A non-radiometric TK1
activity assay (the TK Liaison assay, DiaSorin Inc.) is also
used. Both assays provide clinically valuable information
in humans and dogs with leukemia and lymphoma, par-
ticularly for monitoring therapy and predicting relapse
[15]. The recent development of antibodies against
human TK1 has enabled the determination of serum
TK1 protein levels in different hematologic and solid
tumors such as bladder carcinoma [16], breast carcin-
omas [17], and non-small cell lung cancer [18].
A basic question in this field concerns the structure of
serum TK1 as compared to the cytosolic and recombin-
ant enzyme. There is only one study that describes the
molecular forms of human TK1 in serum [19]. It has
been shown that serum TK1 activity occurs in many
forms with molecular weights ranging from 60 kDa to
730 kDa. Treatment of serum with high concentrations
of the reducing agent dithioerythritol (DTE) in the pres-
ence of 1 mM ATP reduced the molecular weight (MW)
of the enzyme complexes from approximately 730 kDa
to 100–200 kDa [19].
In the present study, full-length canine TK1 was
cloned, expressed in E. coli, purified, and characterized.
Human TK1 was also cloned and expressed in the same
system in order to compare these two enzymes. The sub-
unit structures of recombinant, cytosolic, and serum
TK1 were determined by size exclusion chromatography
and immunoaffinity methods.
Methods
Cloning and expression of full-length canine and human TK
The open reading frame of canine TK1 cDNA is 729 bp
long, encoding 242 amino acids (Accession no XM-
540462). Canine TK1 cDNA was PCR-amplified using an
Incyte canine cDNA clone as the template (Open Biosys-
tems, Lafayette, CO, USA). The amplified PCR fragment
(729 bp) was cloned into the pEXP-5NT/TOPO vector
(Invitrogen, Carlsbad, CA, USA) and sequenced. Full-
length hTK1 cDNA was also cloned into the same vector
and sequenced. The recombinant enzymes were purified
by metal affinity chromatography on Ni-Sepharose resin
as previously described [20].
Cell culture and preparation of cell extracts
CCRF-CEM cells (human T lymphocyte cell line) were
grown in Dulbecco’s Modified Eagle’s medium supple-
mented with 10 % newborn calf serum, 1 mM L-
glutamine and PEST (2.4 IU penicillin and 2.4 μg/ml
streptomycin). Madin Darby Canine Kidney (MDCK)
cells (American Type Culture Collection, ATCC,Manassas, VA, USA) were cultured in ATCC-formulated
Eagle’s Minimum Essential Medium supplemented with
10% newborn calf serum.
Cells (30–100 × 106) were lysed in buffer containing
10 mM Tris/HCl, pH 7.6, 13.7 mM NaCl, 7 mM EDTA,
0.5% NP-40, 2 mM 4-2(aminoethyl)benzenesulfonyl
fluoride hydrochloride (Pefabloc, Fluka) for 30 minutes
at 4°C. The suspension was centrifuged at 16700 × g for
20 minutes at 4°C, and then the supernatant was stored
in aliquots at −70°C after the addition of 20% glycerol.
Anti- TK1 antibodies
Two rabbit polyclonal anti-dog TK1 antibodies were pro-
duced, one using a 28-amino acid (28-mer) synthetic
peptide (amino acids 195–223) as the antigen by Agri-
sera AB (Umeå, Sweden), and the other one using a 16-
amino acid (16-mer) synthetic peptide (211–225) as the
antigen (Figure 1) by GenScript (Piscataway, NJ, USA).
The 31-mer mouse monoclonal anti-human TK1 anti-
body was produced against a 31-amino acid synthetic
peptide (amino acids 194–225) (Figure 1) [3].
Sera from dogs with hematologic tumors were col-
lected at the Small Animal Clinic, Department of
Clinical Sciences, Swedish University of Agricultural
Sciences, Uppsala, and approved by the Swedish Animal
Ethics Committee. Human samples were collected at the
Academic Hospital, Department of Laboratory Sciences,
Uppsala, Sweden, and approved by the Local Ethics
Committee.
Thymidine kinase assay
TK1 activity was measured by a radiochemical method
using the DE-81 filter paper technique as previously
described [5]. [Methyl-3H]-dThd (20 Ci/mmol, PerkinEl-
mer) or [3H]-3’-AZT (12 Ci/mmol, Moravek Biochemicals
Inc, Brea, CA) was used as the labeled substrate. The
standard reaction mixture contained 20 mM Tris–HCl pH
7.6, 2 mM dithiothreitol (DTT), 5 mM MgCl2, 5 mM ATP,
1% bovine serum albumin, and different concentrations of
labeled substrate (ranging from 0.375 μM to 12.5 μM) in a
final volume of 50 μl. One nanogram of recombinant TK1
was used in each reaction. The enzymes were diluted from
a stock solution in Tris-buffered saline (pH 7.6) and 50%
glycerol to 100 μg/ml before use. The specific activity was
expressed as μmol/min/mg. One unit is defined as 1 μmol
of dTMP/AZTMP formed per min and mg protein.
Serum TK1 activity was measured as previously
described [21].
Size exclusion chromatography
Size exclusion chromatography was performed essentially
as described [19] using a Superose 12 column
(1.0 × 30 cm, GE Healthcare, Sweden) attached to a fast
protein liquid chromatography (FPLC) instrument (GE
Figure 1 Amino acid sequence alignment of canine and human TK1. Residues that differ between the two sequences are shaded. Cysteines
that are present in the human but not in the canine sequence are marked with squares. The Zn-binding cysteines are shaded in yellow. GenBank
accession numbers are XM_540461 (dog) and KO_2582 (human).
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1:1 in 0.01 M HEPES/KOH pH 7.6, 0.15 M NH4Cl, and
0.02% NaN3, were injected into the column equilibrated
with the same buffer, and eluted at a flow rate of 0.4 ml/
min. Fractions (0.4 ml) were collected and analyzed. The
column was calibrated with standard proteins: α2-
macroglobulin (720 kDa), β-amylase (200 kDa), bovine
serum albumin (66 kDa), ovalbumin (45 kDa), and horse
myosin (17 kDa).
Immunoaffinity detection of TK1
Cell extracts and recombinant TK fractions were precipi-
tated with 10% trichloroacetic acid (TCA) before western
blot.
Polyclonal anti-dog TK1 antibody (16-mer) and the
mouse monoclonal anti-human TK1 31-mer antibody
were covalently coupled with CNBR-activated Sepharose
4B as described by the manufacturer (GE Healthcare).
FPLC fractions (300 μl) from serum samples were diluted
with 200 μl TBS and incubated with anti-dog TK1 or
anti-human TK1 antibody-coupled Sepharose (50 μl).
The samples were then agitated at 4°C for 4 hours fol-
lowed by centrifugation. The antibody-coupled Sephar-
ose was washed twice with TBS, once with TBS-T, and
once again with TBS. Then, 40 μl sample buffer (contain-
ing 0.5 M Tris–HCl, pH 6.8, 20% glycerol, 10% (w/v)
SDS, 0.1% bromophenol blue, and 10 mM DTT) was
added to the Sepharose and incubated at room
temperature for 20 minutes. The samples were then
heated at 95°C for 5 minutes, and the proteins were
resolved by 12% SDS-PAGE and transferred to a polyvi-
nyl difluoride (PVDF) membrane (GE Healthcare) by a
semi-dry transfer method as described by Invitrogen.
The membranes were probed with a polyclonal anti-dogTK1 antibody (28-mer) or a chicken anti-human anti-
body (31-mer) and immune-reactive polypeptides were
detected by the enhanced chemiluminescence method
(GE Healthcare).Data analysis
The unpaired t-test was used to analyze the data, and a
difference was regarded as significant when the p-
value< 0.05. Kinetic parameters were obtained by fitting
activity data using the Michaelis-Menten equation with
the Sigma Plot Enzyme Kinetics program (SPSS Inc.,
Chicago, IL, USA).Results
Cloning and expression of dog and human TK1
The canine and human TK1 amino acid sequences share
89.3% identity overall. The N-terminal 62 amino acids
are identical, and the two sequences diverge mainly at
the C-terminus, with only 59.5% identity in the last 41
amino acid residues (Figure 1); these residues are not
present in the TK1 structures determined so far [7-9].
Another difference between these two sequences is that
there are 11 cysteine residues in the human and 8 in the
canine sequence; these may be involved in subunit inter-
actions and may contribute to sensitivity to oxidizing
and reducing agents.
Full-length canine and human TK1 cDNAs were
cloned and expressed as fusion proteins with an N-
terminal 6× histidine (His) tag and a TEV site, providing
a 15-amino acid extension to the recombinant protein.
Expression and purification of the His-tagged proteins
were carried out as previously described [20]. The yields
of dog and human TK1 were ~7 mg per liter of culture.
Table 1 Kinetic parameters of dog and human
recombinant TK1
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(M-1 s-1 × 10-6)
n*
dTK1
dThd 0.88 ± 0.1 4.1 ± 0.1 1.81 ± 0.04 2.05 1.3 ± 0.1
AZT 0.70 ± 0.1 3.0 ± 0.1 1.32 ± 0.04 1.89 1.4 ± 0.2
ATP 331± 1.0 4.2 ± 0.3 1.85 ± 0.13 0.006 2.4 ± 0.4
hTK1
dThd 0.83 ± 0.2 2.5 ± 0.2 1.06 ± 0.08 1.40 1.3 ± 0.4
AZT 0.70 ± 0.2 0.95 ± 0.06 0.40 ± 0.02 0.62 1.4 ± 0.2
ATP 243 2.3 0.98 0.004 2.3
Results are mean± standard error of triplicate measurements. Data for human
TK1 with ATP are from one typical experiment. * n Hill coefficient.Substrate specificity, thermal stability, and pH
dependence of recombinant dog and human TK1
The substrate specificity and stability of purified recom-
binant canine TK1 was characterized. Recombinant
human TK1 was also characterized in parallel in order to
compare the two enzymes. Steady-state kinetic analysis
was performed in the presence of an excess ATP and
variable concentrations of dThd or AZT, and the data
were fitted to the Michaelis-Menten equation. The Km
values for dThd and AZT were 0.9 μM and 0.7 μM, re-
spectively, for canine TK1 (Figure 2A), and 0.8 μM and
0.65 μM, respectively, for human TK1 (Figure 2B). Ca-
nine TK1 had a higher turnover rate (kcat) for both dThd
and AZT than did human TK1. The efficiency of AZT
phosphorylation (i.e., the kcat/Km value) was 3-fold
higher for canine TK1 than for human TK1 (Table 1).
Both enzymes showed positive cooperativity with dThd
and AZT, with Hill coefficients of 1.3 and 1.4, respect-
ively (Table 1). The Km values for ATP were 331 μM for
dog TK1 and 234 μM for human TK1. Both enzymes
also exhibited positive cooperativity with ATP, with Hill
coefficients of 2.4 for canine TK1 and 2.3 for human
TK1 (Table 1). When GTP, CTP, or UTP was used as the
phosphate donor the activity was only about 3–10% of
the activity seen with ATP for both enzymes (data not
shown). Thymidine triphosphate (dTTP) acted as an effi-
cient feedback inhibitor, with a relative IC50 value of
16 μM for canine TK1 and 23 μM for human TK1
when assayed with 1 μM dThd and 1 mM ATP (data
not shown).Figure 2 Steady state kinetics of recombinant canine and human TK1
dThd (■) and AZT (●) as the variable substrate. Activity data were fitted to
and error bars are shown.The thermal stability of the two enzymes was
determined at 24, 37, 45, and 50°C, and the optimum
temperatures ranged from 37–45°C (Figure 3). The
activity at 50°C was ~16% lower than that measured at
37°C for canine TK1, and ~40% lower for human TK1
(Figure 3). The effects of pH were evaluated using differ-
ent buffers (i.e., Tris-Acetate pH 6.5, Tris–HCl pH 7.6,
and HEPES/KOH buffer pH 8.1), and there were no
significant differences in the activities of canine and
human recombinant TK1 at these pH values at either 37
or 45°C (Figure 3).
The effect of a reducing agent (DTE) on the activities
of both canine and human TK1 was also investigated;
pre-incubation of the recombinant enzymes (40 ng/ml)
with DTE at 0, 2, or 20 mM on ice for 30 min in the ab-
sence or presence of 1 mM ATP had no significant effect
on the activities of both enzymes (p> 0.05). However,
when the enzymes were incubated with 100 mM DTE. Substrate saturation curve of canine (A) and human (B) TK1 with
the Michaelis-Menten equation. The assays were repeated three times
Figure 3 Temperature and pH effects on the activities of recombinant canine and human TK1. The activities of dog (A) and human (B)
TK1 were measured using [3 H]-AZT as a substrate at different temperatures. The activities of canine (C) and human (D) TK1 were measured with
AZT as substrate at different pH (indicated on the x-axis) and different temperatures: 37 °C (filled bars) and 45 °C (open bars).
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cantly (60% for canine TK1, and 52% for human TK1; p
< 0.05), suggesting that extremely high concentrations of
the reducing agent (e.g., ≥100 mM DTE) may cause
unfolding and loss of activity.
Size distribution and the effect of reducing agent on
recombinant TK1
To study the subunit composition of active TK1, recom-
binant canine and human TK1 were subjected to size-
exclusion chromatography using a Superose 12 column in
the absence of reducing agent in the buffer, in order to
mimic the situation in blood, and to study the effects of re-
ducing agent on subunit interactions. Four micrograms of
freshly isolated recombinant TK1 were injected into the
column and eluted. A total of 24 fractions were collected
and assayed for TK1 activity, and the level of TK1 protein
in each fraction was determined by western blot using a
rabbit polyclonal antibody against canine TK1 or a mouse
monoclonal antibody against human TK1 [3]. The recov-
ery of recombinant canine TK1 was very low with activities
ranging from 0.01–0.42 pmol/min/ml in the collected frac-
tions (Figure 4A, insert), and no protein bands could be
detected in any of the fractions by western blot analysis.
However, when the same amount of recombinant canine
TK1 was pre-incubated with 20 mM DTE for 30 min on
ice, about 85% of the total activity was recovered in the
fractions corresponding to the high MW range 300–
720 kDa (Figure 4A). The canine TK1 protein in these
fractions, detected by western blot analysis, correlated with
the activity profile (Figure 4C). Currently, it is not clearwhy the recovery of the recombinant canine TK1 in the
absence of DTE was so low, but one possible explanation
is that a large fraction of the enzyme precipitated during
chromatography. Nonetheless, reducing agents are appar-
ently required for maintaining the activity of recombinant
canine TK1.
For recombinant human TK1, about 60% of the activity
was recovered in the MW range of 300–720 kDa, and
about 40% in the range of 200–50 kDa (Figure 4B). West-
ern blot analysis showed bands at 25 kDa in the fractions
with TK1 activity (Figure 4D). Bands at 50 kDa were also
detected in these fractions (data not shown). Pre-
treatment with DTE led to a shift towards lower MW, with
56% of the TK1 activity eluting at 50–200 kDa range,
whereas 47% eluted as high MW form of 300–720 kDa
(Figure 4B). The protein levels, detected by western blot,
correlated with the activity in these fractions (Figure 4D).
Thus, the presence of DTE reduced the amount of the
high MW forms of recombinant TK1, and increased the
dimer and tetramer forms, suggesting that disulfide bonds
are involved. These results demonstrate a significant dif-
ference between canine and human recombinant TK1
regarding their sensitivity to reducing agents.
Cellular TK1 is active mainly as dimer and tetramer
Crude MDCK cell extracts were subjected to size-
exclusion chromatography and the native canine TK1
eluted as a broad peak with MWs of 40–100 kDa. There
was also some activity in the fractions at the higher MW
range (Figure 5A). Western blot analysis showed a canine
TK1 band (26 kDa) predominantly in fractions
Figure 4 Quaternary structure of recombinant TK1 and the effect of reducing agent. Untreated (●) or DTE-treated (○) recombinant canine
(A) and human (B) TK1 was analyzed by size exclusion chromatography. Four micrograms of freshly isolated TK1 in 200 μl buffer were injected
into the column and eluted. A total of 24 fractions were collected. TK1 activity in the fractions was determined by radiochemical assay and TK1
protein was detected by immunoaffinity detection method as described in Materials and Methods. Inset: activity profile of untreated recombinant
canine TK1. Arrows indicate the elution position of molecular weight markers. Western blot analysis of FPLC fractions of canine (C) and human (D)
TK1; untreated (−DTE), and DTE-treated (+DTE). The numbers represent FPLC fractions.
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ment of the MDCK extracts with DTE prior to chroma-
tography led to a significant decrease in TK1 activities in
the corresponding fractions (Figure 5A). No TK1 bands
were detected when extracts were pretreated with DTE
(data not shown).
Crude CEM cell extracts were also analyzed by size-
exclusion chromatography, and human TK1 activity was
detected in fractions with MWs ranging from 40–
720 kDa with a minor peak at 500–720 kDa and a major
peak at 40–100 kDa (Figure 5B). Western blotting ana-
lysis showed a clear human TK1 band (25 kDa) in frac-
tions corresponding to MWs of 40–100 kDa and 500–
720 kDa (Figure 5D). When the same crude CEM
extracts were incubated with DTE prior to chromatog-
raphy, the level of TK1 activity eluted at high MW was
reduced, and there was no change in the elution profiles
(Figure 5B). Human TK1 (25 kDa) protein was detected
only in fractions corresponding to the major peak (40–
100 kDa) (Figure 5D). Thus, cellular (native) canine and
human TK1 activity and protein are closely correlated,
and both enzymes are present mainly as dimers and tet-
ramers. Pretreatment with reducing agents inhibited ca-
nine TK1 activity but had little effect on human TK1
activity. These results are similar to previous reports
[5,6].Oligomeric structures of serum TK1 and the effect of
reducing agent
Sera from dogs with hematologic malignancies were ap-
plied to the Superose 12 column. TK1 activity and pro-
tein levels in the collected fractions were determined by
a radiochemical assay and the immunoaffinity method.
About 90% of total TK1 activity was recovered in frac-
tions 1–9, corresponding to a MW range of 300–
720 kDa. A polypeptide with an apparent MW of 26 kDa
was detected in fractions 1–11 and the intensity of the
bands did not correlate with activity levels in these frac-
tions (Figure 6A and C). When the same sera were trea-
ted with DTE (20 mM) prior to chromatography, a
reduction in TK1 activity was observed (Figure 6A), and
the canine TK1 protein was detected in fractions corre-
sponding to high MW but also in fractions correspond-
ing to 25–66 kDa (Figure 6C).
A serum sample from dogs with lymphoma with low
TK1 activity (3 pmole/min/ml) was also analyzed. Only
one activity peak was observed at the high MW and no
TK1 protein could be detected in the western blot ana-
lysis (data not shown).
Sera from human patients with acute lymphocytic
leukemia were pooled and analyzed. Approximately 90%
of the total TK1 activity eluted in fractions 1–9, corre-
sponding to the MW range 300–720 kDa (Figure 6B). A
Figure 5 Size distribution of cytosolic TK1. TK1 activity in each fraction was measured using [3 H]-dThd as substrate. MDCK extracts (A) and
CEM extracts (B) analyzed directly (○) or treated with DTE (●) prior to chromatography. Arrows indicate the elution position of the molecular
weight markers. Western blot analyses of cytosolic canine TK1 (C) and human TK1 (D) in the FPLC fractions using polyclonal anti-dog TK1
antibody or mouse monoclonal anti-TK1 antibody for detection. Pre-treatment with DTE is indicated as +DTE. The numbers represent FPLC
fractions.
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detected in all fractions, and appeared as two peaks, one
in fractions 1–5 and the other in fractions 9–15
(Figure 6D). When the same sample was pre-treated with
DTE, TK1 activity was reduced in the corresponding
fractions and the major activity peak shifted to the MW
range 50–200 kDa (Figure 6B). No TK1 protein bands
could be detected (data not shown).
A serum sample from human patients with relatively
low TK1 activity (4 pmole/min/ml) was also analyzed.
Only one activity peak was detected in the high MW
fractions and no TK1 protein could be detected in any of
the fractions (data not shown).
These results indicated that both dog and human
serum TK1 are present in multimeric forms, as dimers,
tetramers, and higher oligomers, and that the activities
of both canine and human serum TK1 do not correlate
with the level of TK1 protein in the serum. The serum
enzyme is apparently more active in the multimeric com-
plex form. Furthermore, treatment with high concentra-
tions of DTE reduces the size of the complex but also
leads to reduced activity, indicating that serum TK1 is
different from recombinant TK1.Discussion
Recently serum TK1 activity has been used as biomarker
for the diagnosis and prognosis of canine malignant
lymphoma and leukemia [11,15,22,23]. However, the ca-
nine TK1 enzyme has not been characterized. Therefore,
the full-length canine TK1 cDNA was cloned and
expressed in E. coli. Recombinant canine TK1 was purified
and characterized, and compared with human TK1, which
was cloned and purified using the same procedures.
The kinetic properties of canine and human TK1 with
their natural substrate Thd, ATP, and the anti-HIV nucleo-
side analog (e.g., AZT) were investigated. A reason for test-
ing AZT is that it is used in the commercial TK1 Liaison
assay. Canine TK1 had higher Vmax values for all tested sub-
strates than did human TK1. Therefore, the overall effi-
ciency of canine TK1 was higher than that of human TK1.
The high stability and efficiency of canine TK1 when using
AZT as a substrate explains why the TK Liaison assay is
suitable for canine lymphoma and leukemia studies [15,23].
The main focus of this study was to compare the quater-
nary structures of serum TK1 with those of cellular and
recombinant enzymes, and to investigate the effect of
reducing agents on the respective subunit compositions.
Figure 6 Quaternary structures of serum TK1. (A) Thymidine kinase activity in serum fractions from dogs with acute lymphocytic leukemia (●)
injected directly into the Superose 12 column, or pre-treated with 20 mM DTE (○). (B) Thymidine kinase activity in serum fractions from human
patients with acute lymphocytic leukemia (♦) injected directly into Superose 12 or pre-treated with DTE (◊). Arrows indicate the elution position
of molecular weight markers. (C) Western blot analyses of untreated dog serum samples (−DTE) or those pre-treated with 20 mM DTE (+DTE),
using polyclonal anti-dog TK1 antibody. (D) Western blot analyses of untreated human serum samples (−DTE) or those pre-treated with DTE
(+DTE), using monoclonal anti-human TK1 antibody. The numbers represent FPLC fractions.
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human TK1 occur as tetramers in the presence of ATP or
at high concentrations, and as dimers in the absence of
ATP or at low enzyme concentrations [24,25]. Using simi-
lar techniques, we observed that recombinant human TK1
is mainly present in high MW complexes in addition to
dimers and tetramers, and that pretreatment with DTE
increased the extent of dimer and tetramer forms. Recom-
binant canine TK1, on the other hand, appeared to require
reducing agents for proper folding, since in the absence of
DTE only a minor fraction of the analyzed protein was
recovered in high MW fractions, whereas in samples pre-
treated with DTE, about 85% of the activity was recovered
in the high MW form. Both canine and human serum
TK1 eluted mainly as high MW complexes, and the dimer
and tetramer forms had very low activity. Pretreatment
with DTE resulted in >3-fold lower activity. In the case of
human serum TK1, pretreatment with DTE also increased
the proportion of active dimer and tetramer forms. We
found that serum TK1 activity is associated with the TK1
oligomer, and there was no apparent correlation between
serum TK1 activity and protein levels.
However, cytosolic TK1 from cultured canine and
human cells was found mainly in dimer and tetramer
forms, similar to previous reports [24,25]. These results
indicate that the discrepancy regarding recombinant
TK1 quaternary structures in our study compared withprevious reports is not due to technical reasons but may
be due to the conditions used.
Human TK1 contains 11 cysteines and canine TK1 con-
tains 8 cysteines, four of which coordinate with Zn, which
leaves 7 and 4 cysteines, respectively, as free thiol groups.
The structures of TK1-like enzymes, from human, bacter-
ial, and viral origins, are all in tetrameric forms and there
are no intramolecular disulfide bonds observed, since the
enzymes were crystalized in reducing conditions (10 mM
DTT) [7-9]. In solution, in the absence of reducing agent,
it is possible that surface cysteines form S-S bridges be-
tween the monomers, thereby forming oligomers. How-
ever, the oxidation of other residues like tyrosine or
methionine, which lead to the formation of high molecular
weight aggregates, is also possible. If oligomers were
formed entirely through disulfide bonds, they should be
completely reduced to dimer or tetramer in the presence
of high concentrations of reducing agent. The fact that
both serum and recombinant TK1 are persistently present
as oligomeric forms irrespective of the presence of redu-
cing agents suggested that other mechanisms are involved.
In the case of human TK1, disulfide bonds are most likely
involved, since pre-incubation with DTE increased the ex-
tent of dimer and tetramer formation. Furthermore, re-
combinant dog TK1 activity increased upon pre-
incubation with DTE, but there was no reduction in the
oligomeric form, suggesting that the reduction of oxidized
Hanan et al. BMC Biochemistry 2012, 13:12 Page 9 of 10
http://www.biomedcentral.com/1471-2091/13/12residues, not necessarily cysteines, helped the enzyme to
fold into the active form.
In the case of serum TK1, pre-incubation of the serum
samples with DTE resulted in lower overall recovery of
TK1 activity, suggesting that serum TK1 may be cova-
lently associated through disulfide bonds with other
stimulating or stabilizing factors. However, elucidation of
the exact mechanism requires further study.
Conclusions
Serum TK1 is present in sub-picomolar concentrations in
the blood of healthy individuals and is greatly increased in
patients with malignant diseases. Therefore, sensitive la-
boratory methods are needed to obtain the specificity and
sensitivity required to measure this protein. The complex-
ity of the TK1 protein in serum is most likely a major con-
tributing factor to the difficulty in developing effective
determination methods. We found here that serum TK1
exists in a mixture of different molecular sizes, that only a
fraction of the TK1 protein in serum is associated with
TK1 activity, and that reducing agents have negative
effects on serum TK1 activity. These results may help in
the development of TK1 as a biomarker, both in human
and veterinary medicine.
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